U.S. Health and Human Services unit BARDA has awarded the second tranche of its contract with Opiant Pharmaceuticals (NASDAQ:OPNT), valued at ~$2.4M, to accelerate the development of nasal nalmefene for the potential treatment of opioid overdose.
The total agreement is valued up to a maximum of ~$4.6M, the balance to be funded next year.
The company expects to file a U.S. marketing application in Q4 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.